- Stocks
- Healthcare
- NYSE: BMY

Price (delayed)

$64.83

Market cap

$146.5B

P/E Ratio

N/A

Dividend/share

$1.84

EPS

-$0.28

Enterprise value

$172.01B

Bristol Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease,

Bristol Myers Squibb's equity has soared by 184% YoY and by 2.2% from the previous quarter

Bristol Myers Squibb's gross profit has soared by 66% YoY and by 16% from the previous quarter

The net income has dropped by 101% year-on-year but it has surged by 92% since the previous quarter

BMY's debt has soared by 80% year-on-year but it is down by 3.7% since the previous quarter

Bristol Myers Squibb's EPS has shrunk by 108% YoY

What are the main financial stats of BMY

Market
Valuations
Earnings

Shares outstanding

2.26B

Market cap

$146.5B

Enterprise value

$172.01B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.91

Price to sales (P/S)

3.71

EV/EBIT

50.08

EV/EBITDA

13.92

EV/Sales

4.37

Revenue

$39.4B

EBIT

$3.44B

EBITDA

$12.36B

Free cash flow

$11.7B

Per share
Balance sheet
Liquidity

EPS

-$0.28

Free cash flow per share

$5.19

Book value per share

$22.25

Revenue per share

$17.48

TBVPS

$21.44

Total assets

$125.54B

Total liabilities

$75.31B

Debt

$44.95B

Equity

$50.16B

Working capital

$13.81B

Debt to equity

0.9

Current ratio

1.67

Quick ratio

1.43

Net debt/EBITDA

2.06

Margins
Efficiency
Dividend

EBITDA margin

31.4%

Gross margin

71.3%

Net margin

-0.1%

Operating margin

8.8%

Return on assets

0%

Return on equity

-0.1%

Return on invested capital

6.2%

Return on capital employed

3.3%

Return on sales

8.7%

Dividend yield

2.84%

DPS

$1.84

Payout ratio

N/A

How has the Bristol Myers Squibb stock price performed over time

Intraday

0.42%

1 week

-2.57%

1 month

6.02%

1 year

1.04%

YTD

4.51%

QTD

4.51%

How have Bristol Myers Squibb's revenue and profit performed over time

Revenue

$39.4B

Gross profit

$28.1B

Operating income

$3.45B

Net income

-$44M

Gross margin

71.3%

Net margin

-0.1%

The net income has dropped by 101% year-on-year but it has surged by 92% since the previous quarter

BMY's net margin has dropped by 100% year-on-year but it has soared by 94% since the previous quarter

The operating margin has dropped by 68% year-on-year but it has increased by 21% since the previous quarter

Bristol Myers Squibb's gross profit has soared by 66% YoY and by 16% from the previous quarter

What is Bristol Myers Squibb's growth rate over time

What is Bristol Myers Squibb stock price valuation

P/E

N/A

P/B

2.91

P/S

3.71

EV/EBIT

50.08

EV/EBITDA

13.92

EV/Sales

4.37

Bristol Myers Squibb's EPS has shrunk by 108% YoY

Bristol Myers Squibb's equity has soared by 184% YoY and by 2.2% from the previous quarter

BMY's P/B is 49% below its 5-year quarterly average of 5.7 but 16% above its last 4 quarters average of 2.5

The company's revenue has surged by 63% YoY and by 13% QoQ

The price to sales (P/S) is 18% less than the 5-year quarterly average of 4.5 and 2.4% less than the last 4 quarters average of 3.8

How efficient is Bristol Myers Squibb business performance

The ROE has plunged by 100% YoY but it has soared by 92% from the previous quarter

Bristol Myers Squibb's ROA has soared by 100% from the previous quarter but it has plunged by 100% YoY

BMY's return on invested capital has dropped by 76% year-on-year but it is up by 24% since the previous quarter

Bristol Myers Squibb's return on sales has shrunk by 68% YoY but it has increased by 21% QoQ

What is BMY's dividend history

DPS

$1.84

Dividend yield

2.84%

Payout ratio

N/A

Recent dividends

How did Bristol Myers Squibb financials performed over time

BMY's total assets is 67% greater than its total liabilities

The total liabilities has surged by 90% year-on-year but it has declined by 4.6% since the previous quarter

The quick ratio has shrunk by 61% YoY but it has increased by 13% QoQ

BMY's debt is 10% smaller than its equity

Bristol Myers Squibb's equity has soared by 184% YoY and by 2.2% from the previous quarter

BMY's debt has soared by 80% year-on-year but it is down by 3.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.